<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04826562</url>
  </required_header>
  <id_info>
    <org_study_id>09/21</org_study_id>
    <nct_id>NCT04826562</nct_id>
  </id_info>
  <brief_title>Switch to DOVATO in Patients Suppressed on Biktarvy (SOUND)</brief_title>
  <acronym>Sound</acronym>
  <official_title>Switch to DOVATO in Patients Suppressed on Biktarvy (SOUND)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Saint Michael's Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ViiV Healthcare</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Saint Michael's Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      An open-label, pilot study of switching patients to Dovato who are currently taking Bitarvy&#xD;
      who are virological suppressed (HIV-1 &lt; 50 copies/mL&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 2021</start_date>
  <completion_date type="Anticipated">June 2023</completion_date>
  <primary_completion_date type="Anticipated">March 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Virologic Failure</measure>
    <time_frame>48 weeks</time_frame>
    <description>To determine the % of virologic failures (VL ≥ 50 copies/mL at week 48 using the FDA ITT, Snapshot analysis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Virologic Suprresion</measure>
    <time_frame>96 weeks</time_frame>
    <description>To determine the % of subjects remaining virologically suppressed at weeks 48 and 96 using the Snapshot algorithm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Retrospective Baseline Resistance</measure>
    <time_frame>96 weeks</time_frame>
    <description>to determine the percentage baseline resistance after 96 weeks of treatment</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Human Immunodeficiency Virus</condition>
  <arm_group>
    <arm_group_label>dolutegravir/lamivudine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>dolutegravir/lamivudine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dolutegravir/Lamivudine</intervention_name>
    <description>single tablet antiretroviral</description>
    <arm_group_label>dolutegravir/lamivudine</arm_group_label>
    <other_name>Dovato</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Confirmed HIV-1 infection&#xD;
&#xD;
          2. Age of 18 years or older&#xD;
&#xD;
          3. On Biktarvy for at &gt;24 weeks with HIV viral load &lt; 50 copies /mL for &gt; 6 months&#xD;
             immediately prior to enrollment&#xD;
&#xD;
          4. Agree to consistently use an effective method of contraception (see Appendix: Highly&#xD;
             Effective Methods for Avoiding Pregnancies in Females of Reproductive Potential) for&#xD;
             women of child-bearing potential&#xD;
&#xD;
          5. Willingness to sign the informed consent&#xD;
&#xD;
          6. If history of virologic failure must be fully suppressed (HIV-1 RNA&lt;50 copies/mL) for&#xD;
             at least 12 months before screening visit&#xD;
&#xD;
          7. No prior HIV genotype or phenotype available&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Hypersensitivity to dolutegravir and/or lamivudine&#xD;
&#xD;
          2. History of virologic failure while on an integrase inhibitor&#xD;
&#xD;
          3. Taking any medication contraindicated for co-administration with dolutegravir and/or&#xD;
             lamivudine according to manufacturer's current medication package inserts&#xD;
&#xD;
          4. HIV-1 RNA ≥50 copies/mL (confirmed) in the past 48 weeks after initial suppression on&#xD;
             therapy to HIV-1 RNA &lt;50 copies/mL&#xD;
&#xD;
          5. Evidence of Hepatitis B virus (HBV) infection based on the results of testing at&#xD;
             screening for Hepatitis B surface antigen (HBsAg), hepatitis B core antibody&#xD;
             (anti-HBc), hepatitis B surface antigen antibody (anti-HBs) and HBV DNA as follows:&#xD;
&#xD;
               -  Participants positive for HBsAg are excluded.&#xD;
&#xD;
               -  Participants negative for anti-HBs but positive for anti-HBc (negative HBsAg&#xD;
                  status) and positive for HBV DNA are excluded.&#xD;
&#xD;
             Note: Participants positive for anti-HBc (negative HBsAg status) and positive for&#xD;
             anti-HBs (past and/or current evidence) are immune to HBV and are not excluded.&#xD;
             Anti-HBc must be either total anti-HBc or anti-HBc immunoglobulin G (IgG), and NOT&#xD;
             anti-HBc IgM. Participants with a documented history of chronic HBV and current&#xD;
             undetectable HBV DNA while on a Biktarvy are excluded.&#xD;
&#xD;
          6. Pregnant women, women actively seeking to become pregnant, and women of child-bearing&#xD;
             potential who are not using effective contraception&#xD;
&#xD;
          7. Severe hepatic impairment (Child-Pugh C)&#xD;
&#xD;
          8. Critically ill and/or unable to take oral medications&#xD;
&#xD;
          9. Any condition (social or medical) which, in the opinion of the investigator, would&#xD;
             make study participation unsafe for the subject&#xD;
&#xD;
         10. Creatinine clearance &lt; 30 mL/min/1.73m2 via CKD-EPI method&#xD;
&#xD;
         11. ALT &gt; 5x the upper limit of normal (ULN) or ALT &gt; 3x ULN and total bilbirubin &gt;1.5x&#xD;
             ULN (and &gt;35% directed bilirubin)&#xD;
&#xD;
         12. Subjects with an anticipated need for hepatitis C virus therapy with interferon and/or&#xD;
             ribavirin prior to the primary endpoint&#xD;
&#xD;
         13. Unstable liver disease, cirrhosis, and/or known biliary abnormalities (except for&#xD;
             hyperbilirubinemia or jaundice due to Gilbert's syndrome or asymptomatic gallstones)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>James P Fallon, MS</last_name>
    <phone>9738772663</phone>
    <email>jfallon@primehealthcare.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Herbert Galang</last_name>
    <phone>9738775162</phone>
    <email>hgalang@primehealthcare.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Saint Michael's Medical Center</name>
      <address>
        <city>Newark</city>
        <state>New Jersey</state>
        <zip>07102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 28, 2021</study_first_submitted>
  <study_first_submitted_qc>March 30, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 1, 2021</study_first_posted>
  <last_update_submitted>March 30, 2021</last_update_submitted>
  <last_update_submitted_qc>March 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Saint Michael's Medical Center</investigator_affiliation>
    <investigator_full_name>Jihad Slim, MD</investigator_full_name>
    <investigator_title>Chief of Infectious Diseases</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lamivudine</mesh_term>
    <mesh_term>Dolutegravir</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

